TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy, Radiation Therapy, and RSR13 in Treating Patients With Stage III Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed locally advanced unresectable stage IIIA or IIIB non-small cell lung cancer (NSCLC), including: Squamous cell carcinoma OR Adenocarcinoma (including bronchoalveolar cell) OR Large cell anaplastic carcinoma (including giant and clear cell) OR Poorly differentiated NSCLC No small cell carcinoma No distant metastases Measurable or evaluable disease by chest x-ray, CT, or MRI scan Tumors adjacent to vertebral body are eligible if all gross disease is in the radiation boost field No pleural effusion(s) that are exudative, bloody, or cytologically malignant No asymptomatic brain metastases by CT or MRI scan~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life expectancy: At least 12 weeks Hematopoietic: Granulocyte count at least 2,000/mm3 Platelet count at least 100,000/mm3 Hemoglobin at least 10 g/dL (transfusion or epoetin alfa allowed) Hepatic: Bilirubin less than 1.5 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 50 mL/min Cardiovascular: No uncontrolled serious cardiac disease No active congestive heart failure, unstable angina, pericardial effusion, or arrhythmia Pulmonary: FVC or FEV1 at least 50% Resting or exercise SaO2 on room air at least 90% by pulse oximetry Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No active concurrent malignancy within the past 5 years, except: Nonmelanomatous skin cancer Carcinoma in situ of the cervix No serious medical or psychiatric illness that would preclude compliance No active serious infection No concurrent clinically significant peripheral neuropathy No prior significant allergic reaction to drugs containing Cremophor (e.g., cyclosporine or vitamin K) No greater than 10% weight loss in the past 3 months~PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy No concurrent immunotherapy (during radiotherapy (RT) and RSR13 administration) Chemotherapy: No prior systemic chemotherapy No concurrent chemotherapy (during RT and RSR13 administration) Endocrine therapy: No concurrent hormonal therapy (during RT and RSR13 administration) Radiotherapy: No prior radiotherapy to the thorax Surgery: At least 1 week since prior diagnostic thoracoscopy OR At least 3 weeks since prior thoracotomy and recovered No prior total surgical resection Other: At least 3 weeks since other prior investigational agents or devices No prior RSR13

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Elderly Demented Patients: Aromatherapy Complementary to Psychopharmacotherapy Psychological Disorders and BPSD Behavior

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients admitted to the acute geriatric ward;~* patients with a known diagnosis of dementia associated with BPSD or diagnosis performed during hospitalization.~Exclusion Criteria:~* patients with alcohol-based dementia;~* patients with Mild Cognitive Impairment (MCI) - section 4 -;~* patients with language barrier;~* patients already being treated with aromatherapy.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GROUP A - control group (Type: NO_INTERVENTION): 16 patients who respect the inclusion criteria, treated with psychotropic drugs Pro Re Nata.
- GROUP B - aromatherapy group (Type: EXPERIMENTAL): 16 patients included in the inclusion criteria, treated with psychotropic drugs Pro Re Nata and, in a complementary way, with diffusion aromatherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must complete Visit 8 (Day 112) of the double-blind treatment phase of Study EPY-2003 to be eligible for entry into the open-label treatment phase of Study EPY-2006.~Exclusion Criteria:~* Patients who have seizures that cannot be quantitated accurately~* Patients with a history of nonepileptic seizures, serious systemic disease, progressive neurologic disorder, a major psychiatric disorder, status epilepticus in the past 3 months, vagal nerve stimulation discontinuation within the past 3 months~* Patients with a history of drug or alcohol abuse within the past 2 years~* Patients currently taking felbamate, vigabatrin, or tricyclic antidepressants~* and patients who are pregnant or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): RWJ 333369 Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject must have successfully completed either the M02-404 (NCT00077779) or M04-691 (NCT00105300) protocol to be eligible for this study~* Diagnosis of Crohn's disease~* Willing and able to give informed consent~Exclusion Criteria:~* Diagnosis of ulcerative colitis~* Women cannot be pregnant or breastfeeding~* Previous history of listeria infection or untreated tuberculosis~* Previous history of cancer other than successfully treated skin cancer or carcinoma-in-situ of the cervix

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients~* Age greater than or equal to 18 years and less than or equal to 75 years~* Hypertension and metabolic syndrome defined, according to the ATP III/IDF 2005 and ESH/ESC 2007 definitions, as BP greater than or equal to 130/85 mmHg and \<150/95 mmHg (i.e. untreated high normal BP or low range mild hypertension) and at least 2 of the following traits at:~* Abdominal obesity (waist circumference \>102 cm for men and \>88 cm for women)~* Triglyceride level greater than or equal to 150 mg/dL~* High density lipoprotein (HDL) \<40 mg/dL for men and \<50 mg/dL for women~* Fasting blood glucose greater than or equal to 110 mg/dL and \<126 mg/dL (i.e. no type 2 diabetes)~* No anti-hypertensive treatment or treatment with only one anti-hypertensive medication within the last 3 months. Note: treatment with angiotensin II receptor blockers (ARB)or angiotensin-converting enzyme inhibitors (ACE) is not allowed within the last 6 months.~Exclusion Criteria:~* Pregnant or lactating female (prerequisite for female subjects of childbearing potential: adequate contraception)~* Type 1 and type 2 diabetes~* High range mild hypertension (i.e. systolic blood pressure \[SBP\]: 150 - \<160 mmHg and /or diastolic blood pressure \[DBP\]: 95 - \<100 mmHg)~* Moderate (SBP: 160 - 179 mmHg and DBP: 100 - 109 mmHg), severe (SBP: greater than or equal to 180 mmHg and/or greater than or equal to 110 mmHg), or resistant (hypertension resistant to treatment)hypertension~* Secondary hypertension of any aetiology, such as renal disease, pheochromocytoma, or Cushing's syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): A 3-week placebo run-in period.
- 2 (Type: EXPERIMENTAL): Olmesartan medoxomil oral tablets, at lowest study dosage for 52-week double-blind treatment period
- 3 (Type: EXPERIMENTAL): Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 48 weeks.
- 4 (Type: EXPERIMENTAL): Olmesartan medoxomil oral tablets at the lowest dosage for 4 weeks followed by a higher dosage for 4 weeks followed by the highest study dose for 44 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has been diagnosed with type 2 diabetes mellitus~* Has hemoglobin-specific A1c fraction (HbA1c) of 7.1% to 11.0%, inclusive, at screening~* Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening~* Has been treated with diet and exercise alone or in combination with a stable regimen of metformin (MET), a sulfonylurea (SU), a thiazolidinedione (TZD), a combination of metformin and an SU, a combination of metformin and a TZD, or a combination of an SU and a TZD for a minimum of 2 months prior to screening~* Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to screening:~  * Hormone replacement therapy (female subjects)~ * Oral contraceptives (female subjects)~ * Antihypertensive agents~ * Lipid-lowering agents~ * Thyroid replacement therapy~ * Antidepressant agents~ * Drugs known to affect body weight, including prescription medications (e.g. orlistat \[XENICAL®\], sibutramine \[MERIDIA®\], topiramate \[TOPAMAX®\]) and over the counter antiobesity agents~Exclusion Criteria:~* Has ever been exposed to exenatide (exenatide once weekly \[exenatide LAR\], exenatide BID, BYETTA, or any other formulation) or any glucagon-like peptide-1 (GLP-1) analog~* Has received any investigational drug within one month (or five half-lives of the investigational drug, whichever is greater) of screening~* Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment excluded medications:~  * Any dipeptidyl peptidase 4 (DPP-4) inhibitor within 3 months prior to screening~ * Alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days of screening~ * Insulin within 2 weeks of screening or for more than 1 week within 3 months of screening~ * Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Broccoli Sprout Extract Effects on Allergic Inflammation in the Nose

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to provide informed consent~* DEP responder as defined in protocol~* Ability to refrain from consuming cruciferous vegetables 3 days prior to starting study and while on study. Cruciferous vegetables include: Broccoli, Kale, Chard, Kohlrabi, Brussels Sprouts, Parsley, Watercress, Daikon, Cabbage, Rutabagas, Cauliflower, Bok Choy, Arugula, Turnips, Radish, Mustard and Collard greens.~* Allergy skin test positive to cat~* Nonsmoker or ex-smoker of more than one year~Exclusion Criteria:~* Smoking within past year or during study~* Systemic corticosteroid or other immunosuppressive medication use in the previous 3 months or during study~* Intranasal corticosteroid use in the previous month or during the study~* Intranasal antihistamine or cromolyn use in the previous week or during study~* Allergen immunotherapy during the previous 12 months or during study~* Omalizumab use in the previous 12 months or during study~* Systemic antihistamine or leukotriene modifying medication use in the previous week or during study~* History of asthma or any current medical condition that in the opinion of the investigator may compromise the subject's ability to safely participate in the study~* Baseline abnormality of hemoglobin, platelets, leukocytes, serum chemistries, liver function testing, or presence of proteinuria~* A finding during physical examination that, in the opinion of the investigator may compromise the participant's ability to safely participate in the study~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- DEP challenge in subjects consuming BSE (Type: EXPERIMENTAL): DEP will be administered in nostrils of participants who received BSE intervention by drinking 1 cup of liquid containing 1.25 g BSE daily for 4 days, or without consuming BSE.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a cancer diagnosis, receiving chemotherapy, radiation therapy or the combination~* Patients with a current diagnosis of oral mucositis~* Patients with pain and oral dysfunction associated with oral mucositis despite conventional therapy~* Voluntary written consent~* Patient must agree to use of contraception or abstinence from sex during the treatment period and for 30 days after patient's last dose~Exclusion Criteria:~* Patients with known allergy to MB~* Patients taking medications with known significant drug interactions~* Pregnant or lactating patients~* Patients who are cognitively impaired and unable to consent for the study~* Patients with risk of broncho-aspiration based on documented swallowing test by a speech pathologist (if available)~* Patients with known history of G6PD deficiency~* Patients undergoing any other experimental intervention for oral mucositis~* Patients who have no pain or impairment in oral function, patients who are not symptomatic~* Patients with head and neck cancer~* Patients on serotonergic drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (lower dose methylene blue, standard of care) (Type: EXPERIMENTAL): Patients receive lower dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
- Group 2 (medium dose methylene blue, standard of care) (Type: EXPERIMENTAL): Patients receive medium dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
- Group 3 (higher dose methylene blue, standard of care) (Type: EXPERIMENTAL): Patients receive higher dose methylene blue PO to swish and spit for 5 minutes every 6 hours then receive standard of care therapy.
- Group 4 (standard of care) (Type: ACTIVE_COMPARATOR): Patients receive standard of care therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alternative Sedation During Bronchoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults over the age of 18 scheduled for elective flexible bronchoscopy in the endoscopy suite or OR of HUP~Exclusion Criteria:~* History of inability to complete bronchoscopy attributable to inadequate sedation~* Requiring more than 2 LPM supplemental oxygen to maintain SaO2 \> 90%~* History of allergy to study medications~* Pregnancy~* A history of psychosis~* Any condition deemed likely by the pulmonologist or anesthesiologist to pose a significant risk due to elevation of blood pressure, including cerebral/aortic aneurysm, and or ischemic cardiovascular disease~* Bradydysrhythmia deemed significant by the anesthesiologist or pulmonologist~* A diagnosis of significant renal or hepatic impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): midazolam load fentanyl load midazolam demand fentanyl demand benadryl demand
- dexmedetomidine and ketamine (Type: ACTIVE_COMPARATOR): dexmedetomidine load ketamine load dexmedetomidine maintenance ketamine maintenance midazolam demand fentanyl demand benadryl demand

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In overall general good health.~* HSV-2 (Herpes Simplex Virus-2) seropositive at screening.~Exclusion criteria:~* have active lesions consistent with genital herpes.~* previous history of symptomatic genital herpes.~* history of recurrent, undiagnosed symptoms consistent with genital herpes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sequence 1: VALTREX 1 g once daily, Placebo (Type: EXPERIMENTAL): VALTREX 1 g once daily, Placebo
- Sequence 2: Placebo, VALTREX 1 g once daily (Type: EXPERIMENTAL): Placebo, VALTREX 1 g once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have a diagnosis of haemophilia A or B and previously treated with factor Product~* Have started prophylactic Elocta/Alprolix treatment prior to enrollment visit, or at enrollment prescribed prophylactic treatment with Elocta or Alprolix regardless of participation in the study~* Signed and dated informed consent provided by the patient, or the patient's legally acceptable representative for patients under the legal age, Before any study-related activities are undertaken. Assent should be obtained from paediatric patients according to local regulations.~Exclusion Criteria:~* Participation in an investigational medicinal product trial, from four weeks prior to first injection with Elocta or Alprolix to enrollment visit.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Haemophilia A patients (Type: None): Elocta will be prescribed according to local practice and administered by patients with haemophilia A for prophylactic treatment
- Haemophilia B patients (Type: None): Alprolix will be prescribed according to local practice and administered by patients with haemophilia B for prophylactic treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 1% Metformin in Moderate and Severe Periodontitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Systemically healthy subjects, Pocket depth ≥ 5 mm, Clinical attachment level ≥ 4 mm and vertical bone loss ≥ 3 mm on intraoral periapical radiographs, with no history of periodontal therapy in the last 6 months.~Exclusion Criteria:~* subjects allergic to MF, those on systemic MF therapy, subjects with aggressive periodontitis, immunocompromised subjects, use of tobacco in any form, alcoholics, lactating and pregnant females.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Placebo Group (Type: PLACEBO_COMPARATOR): Placebo gel without the active ingredient. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.
- 1% Metformin (Type: ACTIVE_COMPARATOR): 1% Metformin gel. Delivered in biodegradable gel. Frequency- One dose each at baseline, 3 month and 6 month.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete